Mezcalito
••Buy the ticket, take the ride••
Psilocybin is more and more following the footsteps of Ketamine for treatment of mental disorders (even the same indication)?
Breakthrough designation by FDA doesn't mean that it's already generally accepted therapy, but it opens one of the most common psychedelic substances furthermore to serious research and would potentially lead to a rescheduling (currently schedule I, for a substance that's not addictive or causes bodily harm?!?) .
"The research is investigating the optimal dose range for psilocybin in regards to severe treatment-resistant depression."
Phase IIb clinical studies is a quite advanced stage, Rick Strassmann's DMT research in comparison was for sure not more than Phase I.
here's a link, I hope it's ok:
newatlas.com
Breakthrough designation by FDA doesn't mean that it's already generally accepted therapy, but it opens one of the most common psychedelic substances furthermore to serious research and would potentially lead to a rescheduling (currently schedule I, for a substance that's not addictive or causes bodily harm?!?) .
"The research is investigating the optimal dose range for psilocybin in regards to severe treatment-resistant depression."
Phase IIb clinical studies is a quite advanced stage, Rick Strassmann's DMT research in comparison was for sure not more than Phase I.
here's a link, I hope it's ok:
Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA
In an extraordinary step forward for the psychedelic drug research community, the US Food and Drug Administration (FDA) has just given psilocybin therapy for treatment-resistant depression a Breakthrough Therapy designation. This classification suggests the treatment has demonstrated significant…